Key facts
- This page summarizes Ph.D. Noubar B. Afeyan's Form 4 filing for Moderna, Inc. (MRNA).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 08 May 2026, 16:54.
Ph.D. Noubar B. Afeyan - 06 May 2026 Form 4 Insider Report for Moderna, Inc. (MRNA)
- Reporting relationship
- Director
- Issuer ticker
- MRNA
- Reported as of
- 06 May 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 08 May 2026, 16:54:57 UTC
- Prior SEC filing
- 02 Mar 2026
- Next SEC filing
- 22 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ James Dillon, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Ph.D. Noubar B. Afeyan filed Form 4 for Moderna, Inc. (MRNA) on 08 May 2026.
Change
- Previous filing in this sequence was filed on 02 Mar 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001222012
Primary reporting owner
AFEYAN NOUBAR
- Relationship
- Director
- Address
- 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE
- Signature
- /s/ James Dillon, as Attorney-in-Fact
- Signature date
- 08 May 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MRNA
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +12,908
- Change %
- Price
- $0.000000*
- Shares after
- 12,908
- Date
- 06 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,908
- Exercise price
- $48.79
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
This option will become fully vested and exercisable on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.